Literature DB >> 30723584

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.

Jose M Ayuso1,2,3, Regan Truttschel2, Max M Gong2,3, Mouhita Humayun2,3, Maria Virumbrales-Munoz1,2,3,4,5,6, Ross Vitek2,3, Mildred Felder4, Stephen D Gillies5, Paul Sondel4, Kari B Wisinski3, Manish Patankar4, David J Beebe2,3,6, Melissa C Skala1,2,3.   

Abstract

Immunotherapies against solid tumors face additional challenges compared with hematological cancers. In solid tumors, immune cells and antibodies need to extravasate from vasculature, find the tumor, and migrate through a dense mass of cells. These multiple steps pose significant obstacles for solid tumor immunotherapy and their study has remained difficult using classic in vitro models based on Petri dishes. In this work, a microfluidic model has been developed to study natural killer cell response. The model includes a 3D breast cancer spheroid in a 3D extracellular matrix, and two flanking lumens lined with endothelial cells, replicating key structures and components during the immune response. Natural Killer cells and antibodies targeting the tumor cells were either embedded in the matrix or perfused through the lateral blood vessels. Antibodies that were perfused through the lateral lumens extravasated out of the blood vessels and rapidly diffused through the matrix. However, tumor cell-cell junctions hindered antibody penetration within the spheroid. On the other hand, natural killer cells were able to detect the presence of the tumor spheroid several hundreds of microns away and penetrate the spheroid faster than the antibodies. Once inside the spheroid, natural killer cells were able to destroy tumor cells at the spheroid periphery and, importantly, also at the innermost layers. Finally, the combination of antibody-cytokine conjugates and natural killer cells led to an enhanced cytotoxicity located mostly at the spheroid periphery. Overall, these results demonstrate the utility of the model for informing immunotherapy of solid tumors.

Entities:  

Keywords:  Antibody-dependent cell cytotoxicity; Natural Killer cell; microfluidics; organotypic model; solid tumor

Year:  2018        PMID: 30723584      PMCID: PMC6350694          DOI: 10.1080/2162402X.2018.1553477

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  48 in total

1.  Reconstituting organ-level lung functions on a chip.

Authors:  Dongeun Huh; Benjamin D Matthews; Akiko Mammoto; Martín Montoya-Zavala; Hong Yuan Hsin; Donald E Ingber
Journal:  Science       Date:  2010-06-25       Impact factor: 47.728

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  Engineers are from PDMS-land, Biologists are from Polystyrenia.

Authors:  Erwin Berthier; Edmond W K Young; David Beebe
Journal:  Lab Chip       Date:  2012-02-08       Impact factor: 6.799

4.  Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells.

Authors:  Kyriakos V Konstantinidis; Evren Alici; Alar Aints; Birger Christensson; Hans-Gustaf Ljunggren; M Sirac Dilber
Journal:  Exp Hematol       Date:  2005-02       Impact factor: 3.084

5.  Natural killer cells infiltrating colorectal cancer and MHC class I expression.

Authors:  M H Sandel; F M Speetjens; A G Menon; P A Albertsson; P H Basse; M Hokland; J F Nagelkerke; R A E M Tollenaar; C J H van de Velde; P J K Kuppen
Journal:  Mol Immunol       Date:  2005-02       Impact factor: 4.407

6.  Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.

Authors:  Laurent Boissel; Monica Betancur; Weiquan Lu; Winfried S Wels; Teresa Marino; Richard A Van Etten; Hans Klingemann
Journal:  Leuk Lymphoma       Date:  2011-12-06

7.  Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12.

Authors:  Marit Inngjerdingen; Bent Rolstad; James C Ryan
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

8.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

Authors:  S Arai; R Meagher; M Swearingen; H Myint; E Rich; J Martinson; H Klingemann
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

Review 10.  NK cell-based cancer immunotherapy.

Authors:  John Stagg; Mark J Smyth
Journal:  Drug News Perspect       Date:  2007-04
View more
  35 in total

Review 1.  3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models.

Authors:  Maria V Monteiro; Yu Shrike Zhang; Vítor M Gaspar; João F Mano
Journal:  Trends Biotechnol       Date:  2021-09-20       Impact factor: 19.536

2.  Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model.

Authors:  Jeong Min Oh; Hydari Masuma Begum; Yao Lucia Liu; Yuwei Ren; Keyue Shen
Journal:  ACS Biomater Sci Eng       Date:  2022-06-09

3.  Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy.

Authors:  Karla Paterson; Sarah Paterson; Theresa Mulholland; Seth B Coffelt; Michele Zagnoni
Journal:  IEEE Open J Eng Med Biol       Date:  2022-05-27

Review 4.  Engineering Microphysiological Immune System Responses on Chips.

Authors:  Chris P Miller; Woojung Shin; Eun Hyun Ahn; Hyun Jung Kim; Deok-Ho Kim
Journal:  Trends Biotechnol       Date:  2020-02-18       Impact factor: 19.536

5.  Human Tumor-Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells.

Authors:  Jose M Ayuso; Max M Gong; Melissa C Skala; Paul M Harari; David J Beebe
Journal:  Adv Healthc Mater       Date:  2020-01-01       Impact factor: 9.933

Review 6.  Microfluidic Biomaterials.

Authors:  Joe Tien; Yoseph W Dance
Journal:  Adv Healthc Mater       Date:  2020-09-06       Impact factor: 9.933

Review 7.  Microfluidic technologies for immunotherapy studies on solid tumours.

Authors:  K Paterson; S Zanivan; R Glasspool; S B Coffelt; M Zagnoni
Journal:  Lab Chip       Date:  2021-06-15       Impact factor: 6.799

Review 8.  Engineered in vitro tumor models for cell-based immunotherapy.

Authors:  Yuta Ando; Chelsea Mariano; Keyue Shen
Journal:  Acta Biomater       Date:  2021-04-20       Impact factor: 10.633

9.  A bioengineered organotypic prostate model for the study of tumor microenvironment-induced immune cell activation.

Authors:  Sheena C Kerr; Molly M Morgan; Amani A Gillette; Megan K Livingston; Karina M Lugo-Cintron; Peter F Favreau; Logan Florek; Brian P Johnson; Joshua M Lang; Melissa C Skala; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2020-10-16       Impact factor: 3.177

10.  High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.

Authors:  Ilana Berger Fridman; James Kostas; Michal Gregus; Somak Ray; Matthew R Sullivan; Alexander R Ivanov; Smadar Cohen; Tania Konry
Journal:  Acta Biomater       Date:  2021-06-18       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.